132095-54-6

Basic information

• Product Name: 7-Bromo-2-tetralone
• Synonyms: 7-BROMO-3,4-DIHYDRO-1H-NAPHTHALEN-2-ONE;7-BROMO-2-TETRALONE;2(1H)-Naphthalenone, 7-bromo-3,4-dihydro-;7-broMo-1,2,3,4-tetrahydronaphthalen-2-one;7-broMo-3,4-dihydronaphthalen-2-one
• CAS NO: 132095-54-6
• Molecular Formula: C₁₀H₉BrO
• Molecular Weight: 225.08
• Mol File: 132095-54-6.mol

Chemical Properties

• Melting Point: 72-74 °C
• Boiling Point: 319.195 °C at 760 mmHg
• Flash Point: 108.661 °C
• Appearance: /
• Density: 1.511 g/cm³
• Vapor Pressure: 0.000344mmHg at 25°C
• Refractive Index: 1.598
• CAS DataBase Reference: 7-Bromo-2-tetralone(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Bromo-2-tetralone(132095-54-6)
• EPA Substance Registry System: 7-Bromo-2-tetralone(132095-54-6)

Safety Data

• Hazardous Substances Data: 132095-54-6(Hazardous Substances Data)

Usage

Uses

Used in Chemical Research:
7-Bromo-2-tetralone is used as a reactant in various organic synthesis reactions for its functional group, contributing to the development of new compounds and materials in the field of chemical research.
Used in Pharmaceutical Industry:
7-Bromo-2-tetralone is used as an intermediate in the synthesis of pharmaceutical compounds, particularly for the development of drugs targeting specific therapeutic areas.
Used in Material Science:
7-Bromo-2-tetralone is used as a building block in the creation of new materials with unique properties, such as advanced polymers and composites, for applications in material science.

InChI:InChI=1/C10H9BrO/c11-9-3-1-7-2-4-10(12)6-8(7)5-9/h1,3,5H,2,4,6H2

Upstream product

• 74-85-1 ethene 
• 1878-67-7 3-Bromophenylacetic acid 
• 530-93-8 1,2,3,4-tetrahydronaphthalen-2-one 
• 98288-51-8 2-(3-bromophenyl)acetyl chloride 

Downstream Products

• 1364165-64-9 C₁₈H₁₈FNO₂ 
• 885280-71-7 7-bromo-1,2,3,4-tetrahydro-naphthalen-2-ylamine 
• 1364164-16-8 3-(4-fluoroanilino)tetralin-6-carbohydroxamic acid 
• 1221165-94-1 C₁₈H₁₈BrClO₂S 
• 659736-95-5 2-amino-7-bromo-1,2,3,4-tetrahydro-naphthalene-2-carboxylic acid 

Relevant articles and documents

AMINO ALCOHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF

The present invention belongs to the field of medicine, and specifically discloses an amino alcohol derivative represented by Formula I, a pharmaceutically acceptable salt, solvate, polymorph or prodrug thereof. In addition, the present invention also discloses a pharmaceutical composition comprising the above substances, and a use of the substance in the preparation of a medicament for the prevention and treatment of an immune inflammatory disease, or a disease or condition associated with immunological competence such as multiple sclerosis, ALS, CIDP, systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, psoriasis, polymyositis, etc.

MULTICYCLIC COMPOUND INCLUDING NITROGEN AND ORGANIC LIGHT EMITTING DEVICE USING THE SAME

Provided in the present invention are a nitrogen-containing polycyclic compound and an organic light-emitting device using the same. The compound is represented by chemical formula 1. The compound of the present invention can be used as a material of an o

ANTIDIABETIC BICYCLIC COMPOUNDS

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

HETEROCYCLIC GROUP CONTAINED AMINO-METHANOL DERIVATIVE, AND SALT, SYNTHETIC METHOD AND USE THEREOF

The present invention provides a heterocyclic group contained amino-methanol derivative, and salt, a preparation method and use thereof, and belongs to the medical field. The heterocyclic group contained amino-methanol derivative and the salt thereof of the present invention are used for preparing medicines for immune suppression and for the treatment of organ transplant rejection, or medicines for treating immune mediated inflammatory diseases, such as multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis.

HETEROCYCLIC GROUP CONTAINED AMINO-METHANOL DERIVATIVE, AND SALT, SYNTHETIC METHOD AND USE THEREOF

The present invention provides a heterocyclic group contained amino-methanol derivative, and salt, a preparation method and use thereof, and belongs to the medical field. The heterocyclic group contained amino-methanol derivative and the salt thereof of the present invention are used for preparing medicines for immune suppression and for the treatment of organ transplant rejection , or medicines for treating immune mediated inflammatory diseases, such as multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis.

INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF

The present invention relates to semicarbazone or thiosemicarbazone inhibitors of cysteine proteases and methods of using such compounds to prevent and treat protozoan infections such as trypanosomiasis, malaria and leishmaniasis. The compounds also find use in inhibiting cysteine proteases associated with carcinogenesis, including cathepsins B and L.

BICYCLIC SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS

Compounds of formula I: (wherein variables A1, A2, A3, A4, A5, A6, A7, B, E1, E2, E3, E4, E5, G1, G2

SPIROHYDANTOIN TRICYCLIC CGRP RECEPTOR ANTAGONISTS

Compounds of formula I: (wherein variables A1, A2, A3, A4, A5, A6, A7, B1, B2, B3, B4, D1, D2, E1, E2, E3, E4, E5, G1, G2, R6, T, U, V, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

SPIROHYDANTOIN ARYL CGRP RECEPTOR ANTAGONISTS

Compounds of formula (I); (wherein variables A1, A2. A3, A4, A5, A6, A7, B3 E1, E2, E3, E4, E5, G1, G2 and R.6 are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

TRICYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS

The present invention is directed to compounds of Formula I: I (where A1, A2, B1, B2, B3, B4, D1, D2, T, U, V, W, X, Y, Z, R4, R5a?, R5b/su